Novavax Inc
Change company Symbol lookup
Select an option...
NVAX Novavax Inc
ECF Ellsworth Growth and Income Fund Ltd
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
MYD BlackRock MuniYield
WPC WP Carey Inc
ATCO-I Atlas Corp
ATLX Atlas Lithium Corp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Novavax, Inc., along with its wholly owned subsidiaries, Novavax AB and Novavax CZ, is a biotechnology company. The Company promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Closing Price
$11.23
Day's Change
0.32 (2.93%)
Bid
--
Ask
--
B/A Size
--
Day's High
11.32
Day's Low
10.13
Volume
(Heavy Day)
Volume:
10,631,376

10-day average volume:
6,681,412
10,631,376
Latest Earnings Missed Consensus (Q3 ending 09/2022)Next Earnings Announcement
Q3
Announced November 8, 2022
-$2.15Q3 Consensus
of 6 analysts
$1.57Difference from
consensus
-237.12%
Q4 Earnings
will announce
(Unconfirmed) February 27, 2023

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

NVAX's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.